Year Founded
2009
Ownership
Private
Employees
~50
Therapeutic Areas
OncologyPulmonology
Stage
Commercial
Modalities
Small molecule

Aragon Pharmaceuticals General Information

Aragon Pharmaceuticals has developed apalutamide, a second-generation androgen receptor antagonist, which has been approved for castration-resistant prostate cancer. The company also has itraconazole, a fungal CYP51A1 inhibitor, approved for fungal infections.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
San Diego, California
United States

Drug Pipeline

apalutamide
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Aragon Pharmaceuticals's pipeline data

Book a demo

Key Partnerships

Johnson & Johnson, Janssen Research & Development

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Aragon Pharmaceuticals Funding

Deal TypeDateAmountStatusStage
Later Stage VCOct 4, 2012$50.0MCompletedCommercial
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Aragon Pharmaceuticals's complete valuation and funding history, request access »

Aragon Pharmaceuticals Investors

venBio
Investor Type: Venture Capital
Holding: Minority
Topspin Fund
Investor Type: Venture Capital
Holding: Minority
Aisling Capital
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 5 investors. Get the full list »